Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257

June 21, 2015 at 7:47 pm

Clin Infect Dis June 15, 2015 V.60 N.12  P.1842-1851

Editor’s Choice

Ighovwerha Ofotokun, Lumine H. Na, Raphael J. Landovitz, Heather J. Ribaudo, Grace A. McComsey, Catherine Godfrey, Francesca Aweeka, Susan E. Cohn, Manish Sagar, Daniel R. Kuritzkes, Todd T. Brown, Kristine B. Patterson, Michael F. Para, Randi Y. Leavitt, Angelina Villasis-Keever, Bryan P. Baugh, Jeffrey L. Lennox, and Judith S. Currier for the AIDS Clinical Trials Group (ACTG) A5257 Team

In this randomized trial, raltegravir had more of a favorable lipid profile than ritonavir-boosted atazanavir or ritonavir-boosted darunavir–based regimens.

Metabolic syndrome rates increased to the same degree for all 3 regimens.

There was no relationship between ritonavir exposure and lipid levels.

PDF

http://cid.oxfordjournals.org/content/60/12/1842.full.pdf+html

 

Entry filed under: Antirretrovirales, HIV/SIDA, HIV/SIDA Complicaciones, HIV/SIDA HAART, HIV/SIDA Laboratorio. Tags: .

Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy Prevalence of Borrelia miyamotoi in Ixodes ticks in Europe and the United States.


Calendar

June 2015
M T W T F S S
« May   Jul »
1234567
891011121314
15161718192021
22232425262728
2930  

Most Recent Posts


%d bloggers like this: